Synlait Milk today (23 March) sketched out its plans for “recovery” after posting a half-year loss of more than NZ$80m (US$47.1m). A month after issuing a profit warning, the New Zealand dairy and infant-formula business confirmed it had entered the red in the six months to the end of January. The NZ$80.6m net loss compared to a net profit after tax of NZ$4.8m a year earlier. Synlait also booked a loss at the EBITDA level of NZ$35m, a swing from a positive EBITDA of NZ$63m in the opening six months of ...

2026 UBS Global Consumer & Retail Conference March 11, 2026 Forward-Looking Statements Certain statements in this presentation are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of ac ...

Core Insights - Perrigo (PRGO) reported adjusted earnings per share (EPS) of 77 cents for Q4 2025, missing the Zacks Consensus Estimate of 80 cents, representing a 17.2% year-over-year decline primarily due to challenges in the Infant Formula business [1][10] Financial Performance - Net sales decreased by 2.5% year over year to $1.11 billion, slightly exceeding the Zacks Consensus Estimate of $1.10 billion, attributed to weak sales in the Infant Formula segment and losses from exited businesses, partially offset by favorable currency movements [2] - Sales dropped 0.4% year over year, impacted by exited businesses, but benefited from a 2.3% increase due to favorable currency movements; at constant currency, sales fell 4.9%, and organic net sales declined 4.5% [3] Segment Performance - Consumer Self Care Americas (CSCA) segment reported net sales of $697 million, down 6.3% year over year, with organic net sales also declining by 6.3; sales exceeded the Zacks Consensus Estimate of $696 million but fell short of the model estimate of $711.7 million [5] - Consumer Self Care International (CSCI) segment reported net sales of $412.6 million, up 4.7% year over year; however, at constant currency, sales fell 2.1%, and organically, sales declined 1%; CSCI sales surpassed both the Zacks Consensus Estimate and the model estimate [6] Annual Results and Guidance - For the full year 2025, Perrigo reported net sales of $4.25 billion, a decrease of 2.75% year over year, with adjusted net EPS rising to $2.75 from $2.57 in the previous year [7] - Perrigo provided guidance for 2026, expecting All In net sales to decline by 1.5% to 5.5% year over year, with adjusted EPS projected between $2.00 and $2.30; for the CORE business, sales are forecasted to decline by 3% to increase by 1%, with adjusted EPS expected between $2.25 and $2.55 [9] Restructuring and Strategic Developments - Perrigo will restructure its reporting segments into Self Care, Specialty Care, and Infant Formula starting Q1 2026, with the Self Care segment covering various health categories and the Specialty Care segment including Women's Health and Skin Health [13] - In July 2025, Perrigo signed a deal to sell its Dermacosmetics-branded business for up to €327 million, expected to close in Q2 2026 [14] Market Reaction - The lower-than-expected sales and earnings forecasts likely affected investor sentiment, leading to a 1.5% decline in stock price; over the past year, Perrigo shares have decreased by 52.7%, compared to a 14.3% decline in the industry [11]

Core Insights - The company delivered FY2025 adjusted EPS at the midpoint of the updated outlook range, indicating stable performance despite market challenges [1] - The '3-S Plan' is advancing with Perrigo Store Brand OTC and key brands gaining market share in 2025, despite soft category consumption [1] - A new operational enhancement program is being launched, expected to deliver pre-tax annualized savings of $80 million to $100 million [1] - The company will transition to new reporting segments beginning Q1 2026, aligning with its commercial operating model [1] - FY2026 'All In' outlook has been issued, along with the introduction of FY2026 'CORE' outlook, which excludes infant formula and previously announced divestitures [1] Financial Performance - For Q4 2025, net sales were reported at $1.11 billion, reflecting a year-over-year decline of 2.5% [1] - Favorable foreign exchange contributed positively by 2.3%, but this was more than offset by organic net sales decline of 4.5% and the impact of divestitures and exited products, which accounted for a 0.4% decrease [1]

Core Insights - The company reported a slight decline in sales for FY 2025, with total sales of €27,283 million, down 0.3% year-over-year, but like-for-like (LFL) sales grew by 4.5% driven by positive volume/mix and pricing strategies [2][9][10] - Recurring operating income increased by 3.0% to €3,665 million, with a recurring operating margin improvement of 44 basis points to 13.4% [2][19] - The company generated strong free cash flow of €2,799 million, although this was a decrease of 6.8% compared to the previous year [2][21] Financial Performance - FY 2025 sales were €27,283 million, with LFL sales growth of 4.5%, attributed to a 2.7% increase in volume/mix and a 1.8% increase in price [5][9] - Recurring net income attributable to the Group increased by 5.0% to €2,461 million, while total net income decreased by 9.7% to €1,825 million due to non-recurring expenses [2][20] - Recurring diluted EPS rose by 4.6% to €3.80, while reported EPS fell by 10.1% to €2.82 [2][20] Operational Highlights - The company experienced strong sales momentum across all categories and geographies, particularly in China, North Asia & Oceania, and Europe [4][5] - Q4 2025 sales were €6,684 million, reflecting a 4.7% increase LFL, driven by strong volume/mix and pricing [8][10] - The company proposed a dividend of €2.25 per share, up 4.7% from the previous year, reflecting confidence in future performance [23] Strategic Initiatives - The company is focused on reshaping its portfolio, enhancing capabilities in U.S. Medical Nutrition, and advancing microbiome science and digitalization [6][4] - The 2026 guidance aligns with mid-term ambitions, expecting LFL sales growth between 3% and 5%, with recurring operating income anticipated to grow faster than sales [26][7] - The company has been recognized for its sustainability efforts, achieving CDP 'Triple A' List and B Corp certification [5][32]

Core Insights - The company achieved a like-for-like sales growth of +4.5% in FY 2025, driven by positive volume/mix and pricing strategies [6][9][19] - Recurring operating income increased by +3.0% to €3,665 million, with a recurring operating margin of 13.4%, up +44 basis points from the previous year [2][19] - The company reported a net income of €1,825 million, a decrease of -9.7% compared to FY 2024, primarily due to non-recurring expenses [2][21] Financial Performance - FY 2025 sales were €27,283 million, reflecting a -0.3% change on a reported basis, while like-for-like sales grew by +4.5% [2][9] - Recurring net income attributable to the Group increased by +5.0% to €2,461 million, with recurring diluted EPS rising by +4.6% to €3.80 [2][20] - Free cash flow decreased by -6.8% to €2,799 million, with cash flow from operating activities at €3,779 million, down -1.3% [2][21] Operational Highlights - Strong sales growth was observed across all categories and geographies, particularly in China, North Asia & Oceania, and Europe [4][12][14] - The company continued to invest in capabilities, science, and innovation while maintaining a focus on sustainability, achieving CDP 'Triple A' List recognition and B Corp certification [4][31] - The proposed dividend for FY 2025 is €2.25 per share, representing a +4.7% increase from the previous year [22] Strategic Initiatives - The company is advancing its "Renew Danone" strategy, focusing on scaling U.S. Medical Nutrition, enhancing dairy operations, and accelerating digitalization [5][31] - Guidance for 2026 indicates expected like-for-like sales growth between +3% and +5%, with recurring operating income anticipated to grow faster than sales [25][31] - The company is actively reshaping its portfolio and addressing areas requiring further progress, particularly in North America [5][11]

Core Viewpoint - Nestle and Danone are under scrutiny due to significant infant formula recalls, with investors demanding clarity on the financial implications and the companies' responses to the crisis [1] Group 1: Company Responses and Financial Impact - Nestle initiated recalls in December across Europe, Asia, and the Americas due to potential contamination with cereulide, a toxin causing nausea and vomiting [1] - Danone has not commented on the situation, while Nestle is focused on replenishing stocks [1] - Analysts expect Nestle's financial exposure from the recalls to be around €1.6 billion ($1.9 billion), despite the company estimating that less than 0.5% of group sales are affected [1] Group 2: Market Reactions and Reputation Risks - The recalls have negatively impacted both companies' stock performance, with Danone's shares down over 5% this year, while Nestle's shares have shown some recovery [1] - Experts indicate that restoring reputation is critical in the infant formula market, as trust has been compromised among consumers [1] - Competitors like HiPP have seen increased demand due to the recalls, while Nestle's NAN formula has been affected despite being a bright spot in their portfolio [1] Group 3: Regulatory and Competitive Landscape - French authorities have launched investigations into how the recalls were managed, raising concerns about the speed of the response [1] - Danone is particularly vulnerable, with approximately 17% of its total profits derived from infant formula sales in China, where contamination risks are a significant concern for parents [1] - The recalls may lead to a reduction in Nestle's volume-growth forecast by around 100 basis points, as analysts question the company's ability to manage such crises effectively [1]

New Zealand infant formula distributor a2 Milk boosted first-half earnings and raised full-year revenue guidance as sales in China continue to strengthen. https://t.co/IxMAK3dRSm ...

Core Viewpoint - Nestlé SA is increasing production of infant formula to prevent shortages following a contamination crisis that led to a significant recall of products from multiple companies, including Danone SA and Groupe Lactalis [1][3]. Production and Supply Chain - Five Nestlé factories in France, Spain, Germany, Switzerland, and the Netherlands are operating 24/7 to enhance supply, particularly for infants under one year old [2]. - The production boost is a response to the ongoing infant formula crisis, which has seen products from at least five companies recalled in over 60 countries due to contamination concerns [3]. - Other manufacturers, such as HiPP and Holle, are also increasing production to meet rising demand, despite not being affected by the recall [3][9]. Market Impact and Investor Reaction - The recall has negatively impacted publicly-listed formula producers, with stock prices dropping in response to investigations into potential health risks associated with the formula [4][5]. - Nestlé's shares experienced a slight decline, while Danone's stock remained stable after reports indicated no poisoning cases in China, a significant market for Danone [5][6]. Regulatory Actions - China's market regulator has mandated formula makers to test for cereulide, which may help restore investor confidence in the industry [6]. - The investigation into a potential link between a third baby's death in France and Nestlé's formula has further pressured the companies' stock prices [5]. Industry Dynamics - The infant formula market is dominated by major companies, including Nestlé, Danone, and Reckitt Benckiser Group's Mead Johnson, which collectively hold 35% of the global market [9]. - The high market concentration makes it challenging for parents to switch brands, especially during recalls, as many are reluctant to change products that their babies are accustomed to [9]. Production Stability - Other producers, including Danone and Groupe Lactalis, have reported no signs of shortages and are maintaining their current production levels [11]. - Companies like DMK and Hochdorf, which were affected by the contamination recalls, are also keeping their production steady [11].

China’s market regulator has ordered infant formula makers to test for cereulide, a toxin that has triggered precautionary recalls worldwide by some of the largest food companies https://t.co/BIUeCOOtZz ...